Aducanumab: A promising monoclonal antibody for alzheimer's disease

Aducanumab is a novel humanized monoclonal antibody that targets mainly Aβ amyloid plaque and hyperphosphorylated tau proteins. Recently, this drug gets accelerated FDA approval for mild to moderate Alzheimer’s disease but it did not get EMA approval. There have been numerous discussions surrounding the approval of this medicine without a confirmed clinically meaningful benefit.Aducanumab's pharmacokinetics and pharmacodynamic properties, data from the drug's efficacy and safety trials, the consequences of the drug's controversial approval, and the future paths in the therapy of AD patients are all outlined in this narrative review.In this narrative review, total 10 clinical trials are included and these studies show high doses of Aducanumab infusion show modest improvement in delaying the disease process but can’t reverse it. Despite the criticism, Aducanumab had an impact on downstream tau pathology, which may pave the way for an AD combination therapy strategy (anti-tau and anti-amyloid drug).